O11 biomedical, a visionary SME born within BioTex at the RWTH Aachen University, aspires to transform the survival rates and quality of life of patients battling hypercapnia. O11 has developed a minimally invasive, complementary therapeutic approach to hypercapnia to meet the needs of patients and healthcare systems alike: RESPILIQ. This groundbreaking innovation offers a solution by utilizing the human intestine as an alternative respiratory organ to effectively lower pCO2 levels in the blood. o11-biomedical.com